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Abstract
Phenylketonuria, an autosomal recessive Mendelian disorder, is one of the most
common inborn errors of metabolism. Although currently treated by diet, many
suboptimal outcomes occur for patients. Neuropathological outcomes include
cognitive loss, white matter abnormalities, and hypo- or demyelination, resulting
from high concentrations and/or fluctuating levels of phenylalanine. High
phenylalanine can also result in competitive exclusion of other large neutral
amino acids from the brain, including tyrosine and tryptophan (essential
precursors of dopamine and serotonin). This competition occurs at the blood
brain barrier, where the L-type amino acid transporter, LAT1, selectively
facilitates entry of large neutral amino acids. The hypothesis of these studies is
that certain non-physiological amino acids (NPAA; DL-norleucine (NL), 2aminonorbornane (NB; 2-aminobicyclo-(2,1,1)-heptane-2-carboxylic acid), αaminoisobutyrate (AIB), and α-methyl-aminoisobutyrate (MAIB)) would
competitively inhibit LAT1 transport of phenylalanine (Phe) at the blood-brain
barrier interface. To test this hypothesis, Pah-/- mice (n=5, mixed gender; Pah+/(n=5) as controls) were fed either 5% NL, 0.5% NB, 5% AIB or 3% MAIB (w/w
18% protein mouse chow) for 3 weeks. Outcome measurements included food
intake, body weight, brain LNAAs, and brain monoamines measured via LCMS/MS or HPLC. Brain Phe values at sacrifice were significantly reduced for NL,
NB, and MAIB, verifying the hypothesis that these NPAAs could inhibit Phe
trafficking into the brain. However, concomitant reductions in tyrosine and
methionine occurred at the concentrations employed. Blood Phe levels were not
altered indicating no effect of NPAA competitors in the gut. Brain NL and NB
levels, measured with HPLC, verified both uptake and transport of NPAAs.
Although believed predominantly unmetabolized, NL feeding significantly
increased blood urea nitrogen. Pah-/- disturbances of monoamine metabolism
were exacerbated by NPAA intervention, primarily with NB (the prototypical LAT
inhibitor). To achieve the overarching goal of using NPAAs to stabilize Phe
transport levels into the brain, a specific Phe-reducing combination and
concentration of NPAAs must be found.
Our studies represent the first in vivo use of NL, NB and MAIB in Pah-/- mice, and
provide proof-of-principle for further characterization of these LAT inhibitors. Our
data is the first to document an effect of MAIB, a specific system A transport
inhibitor, on large neutral amino acid transport.

xi

1.

Introduction

1.1.

Phenylketonuria

Phenylketonuria (PKU) is an autosomal recessive disorder, which affects more
individuals than any other inherited disorder of amino acid metabolism (U.S.
frequency 1:15,000). The disease was first discovered by Asbjorn Følling in
1934, who recorded high levels of phenylpyruvic acid (keto-phenylpyruvate) in
the urine of two mentally impaired siblings (Følling 1994). In PKU, the deficiency
of phenylalanine hydroxylase, PAH, leads to pathological levels of phenylalanine
(Phe) in the brain and blood, normal to low levels of tyrosine (Tyr), and increased
side-chain conversion of Phe to downstream organic acid metabolites. The
enzyme PAH is responsible for the stereospecific, irreversible hydroxylation of LPhe to the non-essential amino acid tyrosine (Fig. 1.1; Pavon et al. 2006). The
enzyme assembles into a homotetramer forming a 165 kDa multimer of three
domains: regulatory, catalytic and tetramerization domains. Divalent iron (Fe2+)
binds the catalytic domain of the enzyme to achieve full activity, and
phosphorylation at serine 16 of the regulatory domain alters the conformation of
the active site between open and closed forms (Richardson et al. 1993;
Kaufman 1986). PAH catalysis requires the cofactor tetrahydrobiopterin (BH4),
which can exhibit pathway mutations in anabolic or recycling enzymes involved in
its formation, which leads to a milder form of hyperphenylalanemia. The genomic
location of PAH maps to the 12th chromosome, region 12q22-12q24.1 in
H. sapiens, and contains 13 exons (Lidsky et al. 1985). There are more than 500
disease-causing mutations of the PAH gene reported on the PAH locus
database, which present varying degrees of disease phenotype (Williams et al.
2008). PKU is characterized by cognitive loss, white matter abnormalities, hypoor demyelination of neuronal axons, and seizures caused by pathological
phenylalanine levels. Severe and irreversible mental retardation results in cases
of untreated classical PKU (classical PKU characterized by blood Phe levels
>1,200 µmol/L, hyperphenylalaninaemia or mild PKU Phe levels >600 and
<1,200 µmol/L) (Lutz et al. 1982; Lutz et al. 1990).
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Figure 1.1. Phenylalanine metabolism in mammals and the block in phenylketonuria.
Hyperphenylalaninemia results from mutations in the PAH gene (99% of disease
causing mutations) and enzymes responsible for BH4 synthesis and recycling (Erlandsen
et al. 1999). Phenylalanine hydroxylation to tyrosine is blocked, and phenylalanine
undergoes side-chain conversion to keto-phenylpyruvate.

1.2.

Current treatment

PKU patients are required to adhere to a protein-restricted diet, avoid foods high
in phenylalanine content, and maintain lifelong dietary control. However, in the
meta-analysis by Enns et al. 2010, dietary treatment alone resulted in suboptimal
outcomes for neurocognitive, psychosocial and nutritional factors in PKU
patients. Intellectual quotient and executive function were compromised in earlytreated adolescents exhibiting blood Phe variability within the recommended
levels (target blood Phe 120-360 µmol/L; (NIH Consensus 2001). Thus,
metabolic fluctuations in Phe, or associated metabolites, appear to correlate with
cognitive development of PKU patients even in the case of dietary adherence
(NIH Consensus 2001; Enns et al. 2010). Some current research approaches to
the treatment of hyperphenylalanemia seek to stabilize Phe levels through
enzyme replacement therapy, cellular transplantation, or gene therapy. Polyethylene glycolated (PEG) phenylalanine ammonium lyase (PAL), which converts
phenylalanine to the byproduct trans-cinnamate, has already progressed to
2

clinical trials. However, the question of affordability and the feasibility of reaching
the larger PKU population with enzyme replacement remain to be determined.
A pharmacological approach to treatment with the drug sapropterin (Kuvan,
BioMarin Corp.) has shown efficacy in the treatment of BH4-responsive PKU
(Muntau et al. 2002). Sapropterin therapy, as an alternative to dietary
intervention alone, costs approximately $100,000 and $150,000 annually
(estimate for the highest dosage of 20 mg/kg/day; (Harding 2010). New dietary
sources of protein isolated during cheese manufacturing have been shown to
reduce brain and blood phenylalanine. Glycomacropeptide, isolated from cheese
whey, contains little or no phenylalanine, and a high threonine content (Ney et al.
2008), which may reduce intestinal absorption and transport of Phe into the
blood. LNAA supplementation has been shown to improve levels of Phe in the
blood, but this had limited efficacy for patients already adherent to a Phe
restricted medical diet (Schindeler et al. 2007), and may result in negative
nitrogen balance (Dotremont et al. 1995a). Maintaining nutrient balance on a
natural protein-restricted diet remains a challenge (Dokoupil et al. 2011), and
non-adherence can result in cognitive declines, lethargy, depression, and
problems with concentration. PKU patients sometimes require individualized
dietary regimes.
Dietary adherent PKU patients experience suboptimal outcomes from dietary
treatment alone resulting from fluctuating Phe levels (Anastasoaie et al. 2008),
deficiency of certain vitamins and minerals (calcium, folate, thiamine, niacin, and
vitamin B6 intake may be up to 60% below daily recommended intake levels
(Koura et al. 2011), important long chain fatty acids (eg. docosahexanoic acid;
(van Gool et al. 2000), and antioxidants. Some PKU patients require vitamin B6
and B12 supplementation (Hvas et al. 2006), and accompanying deficiency in
folate can lead to moderate hyperhomocysteinaemia (Schulpis et al. 2002).
Increased circulating homocysteine is a risk factor for coronary artery disease
(CAD); folate supplementation is suggested for high-risk CAD patients as strong
correlation between low folate and high homocysteine levels has been suggested
(Lee et al. 2003). Additionally, PKU patients have altered trace metal
consumption including decreased selenium and zinc (Barretto et al. 2008), and
increased iron and copper (Reilly et al. 1990). Selenium is a trace metal required
for selenoenzyme antioxidant species GPx 1 and 3-6, which protects cells from
reactive nitrogen and oxygen species (Tinggi 2008). Low levels of ubiquinone
coQ10 (Colomé et al. 2003) and other lipophilic antioxidants may be responsible
for observed higher lipid peroxidation seen in some PKU patients. Carnitine and
selenium supplementation in the diet of PKU patients for six months reverted
oxidative damage and lipid peroxidation, normalized glutathione peroxidase
activity, and revealed an inverse correlation between oxidative damage and
carnitine levels (Sitta et al. 2011). Whereas the brain is particularly sensitive to
oxidative damage, and PKU patients remain at a high risk for brain pathology, it
is important to prevent a pro-oxidant environment in order to reduce the risk of
3

neurological damage. PKU patients can still develop white matter lesions, as
detected with magnetic resonance imaging (MRI), even with early detection and
dietary treatment (Huttenlocher 2000).
1.3.

Neurological dysfunction

Obligate heterozygous mothers of PKU patients can regulate Phe levels for their
developing fetus in utero. At birth, Phe levels increase rapidly. If left
unregulated, microcephaly, mental retardation, motor and behavioral
disturbances may ensue. The predominant pathology of hyperphenylalanemia
occurs in the central nervous system (CNS), especially white matter in the deep
and subcortical regions of the brain (Anderson et al. 2010). White matter of the
central nervous system is composed of the white fatty substance myelin,
composed of millions of myelinated axons, which are responsible for signal
transmission. Neuropathological features in the CNS of untreated PKU include:
hypomyelination or demyelination, lesions, reactive astrogliosis, and reduced
Purkinje (GABAergic neurons) cell dendritic arborization (Dyer 1999). The
pathogenesis of PKU, although not completely understood (de Groot et al. 2010),
at a minimum, results from the consequences of abnormally high blood and
cerebral phenylalanine and downstream effects on the transport of other large
neutral amino acids, LNAA (Fig. 1.2).
The importance of the blood brain barrier (BBB) in the biochemical regulation of
LNAAs has been implicated in the neuropathology of the disease by magnetic
resonance spectroscopy (MRS), which permits in vivo cerebral Phe
measurements. MRS studies enable correlation between cerebral levels of Phe
and the degree of cognitive impairment and growth in patients (van Spronsen et
al. 2009). Studies by Anderson et al. correlated concurrent and lifetime Phe to
white matter abnormalities (based on the median Phe level over 12 months, r2 =
0.61 (Anderson et al. 2007; Anderson et al. 2010). High Phe levels have also
been shown to inhibit selected enzymes, including tyrosine and tryptophan
hydroxylases, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR; Shefer et al.
2000a), and pyruvate kinase.
Current treatment strategies for PKU are targeted to curtail Phe accumulation in
the blood and brain and its associated pathomechanisms. Among various
systems of amino acid transporters identified (system A transporter (SAT),
ASCT, y+, x-c, and b0,+; see Fig. 1.5), transport of Phe and other LNAAs takes
place via a system of L-type amino acid transporters (Babu et al. 2003).
1.4.

L-type amino acid transporter, LAT1

Four mammalian LATs (1-4) comprise the system of transporters in mammals
responsible for the movement of LNAAs. System L transporters are Na+ and Cl4

independent, heterodimeric, transmembrane proteins responsible for the
basolateral movement of amino acids. Functional expression requires
association with the type II glycoprotein 4F2 heavy chain, 4F2hc/CD98 (Rossier
et al. 1999). The two distinct genes corresponding to the heavy and light chain
(LAT1) units are the solute carrier SLC2A2 and SLC7A5, respectively (Verrey et
al. 2004). LATs are expressed with varying tissue specificity and substrate
affinity (Table 1.1). Phenylalanine and eight other LNAAs traverse the BBB with
high affinity (Km = 12 to 50 µM, His, Phe, Leu, Met, Trp, Ile, Tyr, Val; Gln with 2
orders of magnitude lower affinity Km = 1.6 mM) via LAT1 facilitated amino acid
exchange (Fig. 1.2, Table 1.1). LAT1 has widely expressed mRNA levels. LAT2 exhibits broad LNAA usage and high affinity (Km = 30 to 50 µM) for Tyr, Phe,
Trp, Thr, Asn, Ile, Cys, Ser, Leu, Val, and Gln), lower affinity (180 to 300 µM) for
His, Ala, Met, and Gly, and is primarily expressed in the small intestine, kidney,
brain and placenta (Segawa et al. 1999). The affinity of LAT1-4 for LNAAs is
high in comparison to blood concentrations (Km value < 200 μM) guaranteeing
their saturation at normophysiological blood amino acid levels. LAT1 and LAT2
(the latter an isoform of LAT1) are both expressed in the brain and facilitate
tissue uptake from the blood capillaries; system L is crucial to cellular
homeostasis and transport of neutral amino acids.
Table 1.1.
System L-type amino acid transporters

Transporter

Tissue
Expression

Amino Acid
Selectivity

Selected
Kms (µM)

Citations

LAT-1

Brain,
spleen,
placenta,
testis, fetal
liver

Large neutrals:
F,Y,W,M,H,L,I,V

Phe 14
Leu 20
Tyr 28
Trp 21
Met 20
His 12

(Kanai et
al. 1998)
(Yanagida
et al.
2001)

LAT-2

Brain,
small
intestine,
kidney,
placenta

Large and small
neutrals:
F,Y,W,L,I,V,T,N,C,S,Q
(M,H,G,A)

Phe 45
Leu 119
Tyr 36
Trp 58
Met 204
His 181

(Segawa
et al.
1999)

LAT-3

Liver,
pancreas,
skeletal
muscle

Amino acids (and
amino acid alcohols):
F,L,I,V

Phe 6*
Leu 8*

(Babu et
al. 2003)
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Table 1.1 (continued)

Transporter

Tissue
Expression

Amino Acid
Selectivity

Selected
Kms (µM)

Citations

LAT-4

Kidney,
placenta,
leukocytes

Large neutrals:
F,L,I,M

Phe 178*
Leu 103*

(Bodoy et
al. 2005)

Mammalian LATs: Tissues in which the transporters are expressed, amino acids
transported by each LAT, and the affinity of the transporter for selected amino acids are
summarized. LAT2 is an isoform of LAT1, and LAT4 is an isoform of LAT3. The lower
affinity amino acids transported by LAT2 are shown in parentheses. LAT3 and LAT4
have both high and low affinity forms (regulated by phosphorylation). *High affinity Km
listed for LAT3 and LAT4. Km describes the concentration at half-maximal velocity in the
absence of competitors (measured in Xenopus oocytes).

Supraphysiological levels of Phe in PKU are predicted to saturate the LAT
transporters and competitively exclude other LNAAs from transport. Cerebral
protein synthesis is dependent upon concentrations of essential amino acids
(Nishihira et al. 1993), normal transport and metabolic machinery, and multiple
other functions critical for brain development. Transport inhibition of LNAAs
during hyperphenylalaninemia may influence the following: reduced cerebral
protein synthesis due to abnormal LNAA homeostasis, neurotransmitter
synthesis (dopamine, serotonin), and proteins necessary for axonal myelination,
such as myelin basic protein (MBP) ( Antoshechkin et al. 1991; Shefer et al.
2000b; Joachim Pietz et al. 2003; Hörster et al. 2006; Ogawa et al. 2006).
Transport competition during hyperphenylalaninemia occurs at the blood brain
barrier and gut endothelium, where the large neutral amino acid transporters
selectively bind and transport amino acids transcellularly. The Michaelis-Menten
constant (Km) for LAT1, defined as the ½ maximal transport saturation,
represents the affinity of the LAT1 system for amino acid transport. Phe is
transported with high affinity on all four LATs. LAT1 has a Km for phenylalanine
of 11 µmol/L (measured in rat brain in situ), and with blood phenylalanine levels
in classical phenylketonuria fluctuating at or above 1,200 µmol/L, Phe can easily
oversaturate the LAT system and exclude other LNAAs through mass action
alone (Fig. 1.2; Kanai et al. 1998). Certain non-physiological amino acids,
NPAAs, have proven effective at competing with Phe for LAT1 transport.

6

Figure 1.2. LNAA trafficking on LAT1 in PKU: Schematic diagram of the LAT1
transporter at the blood brain barrier. Accumulation of supraphysiological levels of amino
acids in PKU are shown with downstream outcomes related to disrupted LAT1 transport:
monoamine neurotransmitters (serotonin, dopamine), the brain’s primary methyl donor,
S-adenosylmethionine, and histamine. High levels of phenylalanine and leucine,
respectively, contribute to depletion of histidine, methionine, tryptophan (Trp), and
tyrosine (Tyr) in the brain due to competitive exclusion via LAT1 oversaturation at the
blood brain barrier. Lower histidine decarboxylation in the brain may alter histamine
neurotransmission from the tuberomammillary nucleus to other brain regions
(immunological function when released from mast cells which leads to vasodilation and
permeability; however, mast cells are less numerous in the brain than other tissues
(Brown et al. 2001). Altered synthesis of monoamine neurotransmitters serotonin and
dopamine result from depletion of Trp and Tyr (Fig. 1.3). Adapted from (Strauss et al.
2010).

Figure 1.3. Dopamine (DA) and Serotonin (5-HT) synthesis and metabolism.
Abbreviations: L-dihydroxyphenylalanine (L-DOPA); 5-hydroxytryptophan (5-HTP); 3,4dihydroxyphenylacetic acid (DOPAC); homovanillic acid (HVA, DA turnover is measured
as the ratio of (DOPAC + HVA)/DA; 3- methoxytyramine (3-MT, a DA metabolite

7

released into the synaptic cleft, DA release into the synaptic cleft, 3-MT/DA); 5hydroxyindoleacetic acid (5-HIAA; serotonin turnover measured as 5- HIAA/5-HT).

1.5.

Non-physiological amino acids, NPAAs

Competition between LNAAs for transport into rat brain was documented more
than 60 years ago (Christensen et al. 1948), and competition between Phe and
Leu for uptake across the BBB has been confirmed in PKU patients at differing
Phe levels (Knudsen et al. 1995). Pietz and coworkers (1999) were the first to
demonstrate that LNAA supplementation in diet could decrease Phe levels (Pietz
et al. 1999). Others (Matalon et al. 2006; Michals-Matalon et al. 2007) have
successfully modified this diet with improved outcomes in PKU patients, yet the
long term use of these diets may be thwarted by negative nitrogen balance
(Dotremont et al. 1995; van Spronsen et al. 2010). These observations suggest
that therapeutic competition for amino acid transport into the brain of individuals
with aminoacidurias such as PKU may be feasible, as has been suggested by
others ( McKean et al. 1968; Tews et al. 1986; Tews et al. 1990; Tews et al.
1991). Nonetheless, a systematic study of this approach has not been
presented. Zinnanti and coworkers (2009) recently verified the feasibility of this
therapeutic approach employing dietary supplementation with the NPAA
norleucine (NL) in mice with maple syrup urine disease (Fig. 1.2, 1.4.A). NL
supplementation in this model (in which branched-chain amino acids Leu, Ile and
Val accumulate) extended lifespan while improving both brain biochemistry and
neurobehavioral outcomes. The work of Zinnanti extended earlier reports by
Tews and Harper (1986), who showed that NL supplementation effectively
lowered Phe level in rat brain. Similarly, Ennis and coworkers (1994)
demonstrated that another NPAA, alpha-aminoisobutyrate (AIB; Fig. 1.4.C) could
compete with Phe for transport via LAT1. LAT1 also traffics α-methyl amino
acids such as α-methylphenylalanine, α-methyltyrosine, and 3-O-methyldopa,
which were shown to block the uptake of Phe (Uchino et al. 2002). Methylaminoisobutyric acid, MAIB (Fig. 1.4.D), is specific for the small neutral amino
acid, alanine-preferring system A transporter (SAT), which is a sodiumdependent carrier that has some affinity for LNAAs such as Phe (Hargreaves and
Pardridge 1988; Grewer and Grabsch 2004; Rutter et al. 2007). Finally, NB (Fig.
1.4.B) represents the prototypical NPAA inhibitor of the LAT 1-4 system (Table
1.1), yet it has never been examined systematically as a therapeutic regimen in
any mammalian system or animal model.
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Figure 1.4. Non-physiological amino acids (NPAA): A, norleucine (NL); B, 2aminonorbornane (NB); C, 2-aminoisobutyric acid (AIB); D, N-methyl-2-aminoisobutyric
acid (MAIB). MAIB is a selective inhibitor of the A-system (see above).

Figure 1.5. Amino acid transport systems at the blood-brain barrier (BBB). Transport
system nomenclature uses one letter amino acid codes: A, alanine preferring, ASC,
alanine-serine-cysteine preferring, and L1, leucine preferring. Amino acids transported
are listed beside each transport system, and non-physiological amino acid competitors
are shown in red (norbornane (NB) is also called 2-aminobicyclo-(2,1,1)-heptane-2carboxylic acid (BCH)). Gray shading signifies Na+-dependent transport, and white
boxes denote facilitative amino acid exchange.
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1.6.

The Pahenu2 mouse

To determine whether NPAA inhibitors of the LAT1 transporter will reduce
cerebral phenylalanine, and how LAT1 inhibition might subsequently alter
transport of other LNAAs, NPAAs will be administered to the Pahenu2 mouse. The
Pahenu2 mouse harbors a single nucleotide polymorphism converting a highly
conserved phenylalanine to serine (F263S) within the enzyme catalytic domain
(McDonald and Charlton 1997). Although PAH mRNA and protein are detectable
in the liver, the enzyme is inactive, and homozygous animals are consistently
hyperphenylalaninemic with cognitive and growth retardation ( McDonald et al.
1990; UK PubMed Central 1995; Zagreda et al. 1999). Cerebral protein
synthesis is decreased in this model (Smith et al. 2000), as are neurotransmitter
concentrations in brain extracts (Pascucci et al. 2002; Joseph et al. 2003).
Additionally, decreased content of branched chain amino acids (Val, Ile, Leu) has
been documented in the brain of hyperphenylalaninemic animal models created
by administration of phenylalanine metabolism inhibitors (Puglisis-Allegra et al.
2000; Pascucci et al. 2002). The Pahenu2 mouse is the disease model of PKU
most relevant to the human disorder and therefore most suitable for preclinical
evaluation of dietary LAT inhibitors to assess efficacy.

10

2.

Objective

In this thesis project, the objective was to use non-physiological amino acids
(NPAAs) to selectively restrict Phe transport into cerebral tissue. The selected
amino acids used in this study (NL, NB, AIB, and MAIB) are known to, or
predicted to, inhibit the different LATs. The main objective of this work is to
provide preclinical data leading to translational outcomes that will provide a new
treatment approach to PKU. The hypothesis is that a particular combination of
NPAA inhibitors of the LAT-1 system can be found to selectively preclude Phe
from the brain. Ideally, this dosage would have minimal impact on the levels of
other LNAAs in the brain. Such a treatment approach could have important
clinical relevance for adolescents and adults that have difficulty adhering to a
Phe-restricted diet. Blocking Phe transport could also improve suboptimal
outcomes seen in some patients treated with the PKU diet alone.

11

3.

Materials and methods

3.1.

Husbandry and subject number

To breed offspring for the experiment, polygamous breeder pairs were
established with male Pah-/- and female Pah+/- subjects. Offspring were
genotyped with tail clip extracted DNA performed at weaning (20 days of life).
This was followed by PCR and restriction endonuclease digestion with BsmAl,
and then visualized by agarose gel (4%) electrophoresis, as described (Zagreda
et al. 1999). Since amino acid levels are similar between Pah+/+ and Pah+/subjects, Pah+/- subjects were used as controls, obviating the need for additional
husbandry to generate Pah+/+ subjects. This is consistent with our laboratory’s
adherence to the best practices of animal usage suggested by the Association
for Assessment and Accreditation of Laboratory Animal Care (AAALAC), and the
objective of replacing, reducing and refining the use of animals in biomedical
research. An n=5 sample size facilitated simple parametric statistical analysis (ttest, ANOVA). This sample size was based on power calculations utilized in an
unrelated study of MSUD mice in which hepatocyte transplantation was the study
parameter. In that work, an n=5 sample size (hepatocyte-transplanted MSUD
mice vs. PBS-transplanted MSUD mice) enabled us to detect a 20% reduction in
the metabolic parameter alloisoleucine (pathognomonic for MSUD) with a
significance of p<0.05. Accordingly, this number of subjects was adopted in the
current study. (Protocol approval for studies with vertebrate animals IACUC
L0214)

3.2.

NPAA administration

NPAAs were administered to mice in their food to assess their potential use as
interventions in PKU. Dietary compounds included 5% α-aminoisobutyric acid
(AIB), 5% DL-norleucine (NL), 0.5% norbornane (2-aminobicyclo(2,2,1)heptane2-carboxylic acid, NB), 3% α-methyl-aminoisobutyric acid (MAIB) (Sigma
Aldrich), and control chow (2018 Teklad Global Rodent Chow, 18% protein, and
extruded sterilizable 2018X). We employed 5% (w/w) NL and AIB based upon
the previous report of Zinnanti et al (2009) employing MSUD mice. The expense
of NB (~$350/g) prohibited its use at 5%; accordingly, we chose 0.5% w/w (a
serendipitous choice). Two separate feeding experiments were performed. The
first experiment with NL, NB and AIB used regular 18% mouse chow from
Tekklad (18R), and the second with MAIB used sterilizable, extruded 18% protein
chow. Chow was made in batches of 300 g. 18R was made with 300 mL of
filtered water and mixed with drug and dehydrated 24 hours at 46°C. 18X chow
was made with 500 liters of autoclaved water and dehydrated 20-24 hours at
46°C. The compounds themselves were not autoclaved. Dietary intervention
was instituted at 3.5 weeks of age (post weaning and genotyping) and
maintained for 3 weeks. Animals were housed under a 12 hour light/dark cycle
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with ad lib access to food and water. Mouse weights were recorded three times
weekly, and food consumption calculated weekly. Blood spots were collected on
Day 0 via saphenous vein puncture and capillary tube collection and spotted onto
newborn screening blood spot cards (GE Healthcare) stored at -20°C. These
were collected with the intention of looking at temporal changes in amino acid
levels in blood without sacrificing the animal. At week three sacrifice, terminal
blood spots, brain halves, and sera were collected into 1.5 mL tubes. Brain
halves were flash-frozen with liquid nitrogen and stored at -80°C.

3.3.

High performance liquid chromatography, HPLC

Catecholamine metabolites in Pah-/- and Pah+/- mouse ½-brain (homogenized
with a 1:5 dilution of ice cold 0.1M perchloric acid, dithioerythritol, and
diethylentriamine pentaacetic acid) were quantified by reverse-phase HPLC with
electrochemical detection. Dihydroxyphenylacetic acid (DOPAC), 3methoxytyramine (3-MT), homovanillic acid (HVA), dopamine (DA), 5hydroxyindole-3-acetic acid (5-HIAA), 3-O-methyldopa (3-OMD), and serotonin
(5-HT) represent the key monoamines for our NPAA interventions (CoulArray)
(Ogburn et al. 2006); HPLC and LC-MS analysis Dr. T. Bottiglieri, Baylor
University Medical Center, Dallas, TX).

3.4.

Liquid chromatography tandem mass spectrometry

LNAAs in serum and ½-brain were quantified using liquid chromatography-mass
spectrometry (LC-MS) with electrochemical detection. Standards of Sadenosylmethionine (SAMe), S-adenosylhomocysteine (SAH), betaine (Bet),
choline (Cho), methionine (Met), tryptophan (Trp), and tyrosine (Tyr) (Sigma).
Stable isotope internal standards included betaine-d3 (BET-D3), choline-d4
(CHO-D4), methionine-d3 (MET-D3), tryptophan-d3 (TRP-D3), and tyrosine-d7
(TYR-D7) purchased from Cambridge Isotope Laboratories or CDN Isotopes
INC. Stable isotope standards facilitated very accurate quantitation.
Heptafluorobutyric acid and formic acid were purchased from Fluka. Ammonium
acetate was purchased from Sigma, and Optima LC/MS methanol from Fisher
Chemicals. The HPLC system consisted of a complete Shimadzu Prominence
HPLC system with a SCL-10Avp controller. The instrument used for analysis
was an ABI 4000 QTRAP LC/MS/MS system. Three groups of stock standards
were prepared in 0.1 M HCL at a concentration of 1 mM and fourth group was
prepared in 0.1 M HCL at a concentration of 4 mM. All stable isotope internal
standards were prepared in 0.1 M HCL at a concentration of 1 mmol/L and stored
at -80ºC. All four calibration standard groups were stored at -80C until needed.
From these stock solutions a five level standard curve was prepared by diluting
stock solutions in Type 1 water. Tissue samples that were previously
deproteinized 1:5 with ice-cold 0.1 M PCA were thawed and spun. Samples
were prepared by the addition of 150 µL mobile phase A containing 20 µmol/L
13
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H3-SAMe to 50 µL of standard or plasma and mixed by vortex. 150 µL of
sample mixture was added to a Microcon YM-10, 10 kDa NMWL microcentrifugal
filter unit and centrifuged for 15 min at 14800 x g at 4ºC. Sample filtrate was
removed and transferred to autosampler plate for analysis. 5 µl were injected
into the LC-MS system, described above. Solvents for HPLC were: A, 4mM
ammonium acetate, 0.1% formic acid, 0.1% heptafluorobutyric acid (pH=2.5); B
100% methanol and 0.1% formic acid. All analytes were separated on a 250 x
2.0 mm EZ-faast analytical column (Phenomenex) maintained at 33°C at a flow
rate of 250 μL/min, with a binary gradient and a total run time of 12 min. The
initial gradient condition was 75% A: 25% B and was ramped in a linear fashion
to 100% B in 6 min and held constant for 1 min. At 7.1 min the mobile phase
was reset to initial conditions for 7 minutes. The flow from the column was
delivered to the electrospray ionization (ESI) source from the period of 3 to 8 min;
otherwise the flow was diverted to waste. The compounds were detected by
multiple reaction monitoring (MRM) using positive ESI with a dwell time of 30 ms.
The curtain gas was set at 15 L/min, and source gas 1 and 2 were set at 60
L/min. The heater was set to 700ºC with an ionspray voltage of 5,000 V and
collision gas (nitrogen) was set at 3.5 x 10-5 Torr. All data were collected using
Analyst software version 1.4.2 (Slocum et al. 1991; Puglisis-Allegra et al. 2000;
Ogburn et al. 2006).

3.5.

Statistical analysis

Metabolite data was grouped with respect to genotype (Pah+/-, Pah-/-) in order to
correlate NPAA effects under normo- and hyperphenylalaninemic conditions.
Since we employed a column statistical approach (ANOVA with Tukey post-hoc),
grouping by genotype significantly reduced data analysis. Analysis was
performed with Graphpad Prism V5.
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4.

Results

4.1.

Health and food consumption

As a simple gauge of animal well-being and to verify intake of the drug, food
consumption, and body weights were recorded. Food and water consumption,
and body weights, did not differ significantly with respect to control cohorts as a
function of treatment intervention (Table 4.1), except 5% NL. One subject died,
and another was near death at sacrifice for NL. There were no outward
phenotypic differences for subjects consuming NB, AIB or MAIB, as estimated
from visual health inspections. Conversely, subjects consuming 5% NL
displayed some motor impairment, but movement anomalies were not yet
quantified.
Table 4.1. Health and food consumption
Diet, genotype, average weight gain (3 week duration), and
food consumption (Week1, 2, 3).

Diet
18%
protein
AIB 5%
NL 5%
NB 0.5%
18X
protein
MAIB 3%

4.2.

Genotype

Ave.
weight
gain (g)

Wk 1

Wk 2

Wk 3

Het (n=7)
Mut (n=5)
Het (n=5)
Mut (n=5)
Het (n=5)
Mut (n=4)
Het (n=5)
Mut (n=5)

3.83
2.84
4.72
2.16
1.64
-0.43
5.28
6.38

3.57
3.94
2.55
1.86
1.95
2.06
2.99
2.51

3.16
3.91
2.98
1.64
2.74
2.35
3.06
2.89

3.12
3.49
3.16
2.28
no data
2.57*
3.05
2.90

Het (n=5)
Mut (n=5)
Het (n=4)
Mut (n=6)

11.96
4.88
9.05
8.08

2.41
2.04
1.93
1.84

3.69
3.49
2.75
2.57

3.03
2.44
2.63
3.71

Amino acids in brain

Amino acid levels in the brain were measured to determine the effectiveness of
NPAA LAT1 competitors to reduce Phe, as well as to gauge outcomes on other
LNAAs. NL, NB, and MAIB feeding significantly lowered brain Phe levels in Pah/subjects, with NL displaying the largest reduction (even in Pah+/- subjects);
conversely, 5% AIB was not effective at reducing brain Phe. Although none of
the dietary interventions altered Trp levels (an intriguing observation in view of
15

catecholamine disturbances; see Fig. 4.3.a), pronounced effects on Tyr, BCAA
and Met were seen (Fig. 4.1.a,b). Tyr levels were significantly decreased in both
genotypes during NL and NB interventions, while these diets had a more
pronounced effect on BCAAs in Pah+/- mice (although NL did reduce BCAA levels
in Pah-/- subjects). MAIB decreased Phe and Tyr levels significantly in the Pah-/subjects (p<0.005 and p<0.05 respectively), and did not significantly alter total
BCAA (sum of Val, Leu, and Ile). NL, NB, and AIB decreased Met levels in Pah+/subjects, and both NB and AIB feeding resulted in decreased Met levels in Pah-/subjects. MAIB did not alter Met levels (Fig. 4.1.b). NL intervention significantly
reduced SAMe, in both genotypes. We extended SAMe studies by measuring
the associated sulfhydryl analogue, S-adenosylhomocysteine (SAH; see bottom
right quadrant, Fig. 4.2.), in which the effects of NL on SAMe were reproduced
with respect to SAH. As for SAMe, SAH levels were not different by genotype in
control cohorts (no NPAA). Moreover, we found a hypercorrection of SAH levels
with NB feeding (Fig. 4.2.a; p<0.05 with respect to control). Although no
significant difference in SAMe was observed with MAIB, brain SAH levels were
decreased (p<0.001).
We next performed t-test analyses of each NPAA diet as a function of genotype
(not shown in Fig. 4.1.a). These analyses revealed significant differences
between Pah+/- and Pah-/- subjects as follows: Phe (control and all diets, as
expected); Tyr, only AIB and NB; Trp and BCAAs, only in control; Met, control
and AIB; SAMe and SAH (Fig. 4.2.a,b), only AIB, and SAH only for MAIB. Of
interest (Fig. 4.1.a) was the observation of a lack of a significant difference for
Tyr with respect to genotype (in the absence of dietary intervention), perhaps
explaining why dopamine anomalies are less pronounced than serotonin defects
in Pah-/- subjects
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Figure 4.1.a. Brain LNAAs and SAMe as a function of diet (NL, NB, AIB) and genotype
(T, Pah+/; M, Pah-/-). Brain LNAA levels, and that of the methionine derivative Sadenosylmethionine (SAMe), are shown in Fig. 4.1. SAMe measurements were
proposed to assess possible downstream effects if alterations of Met levels were
encountered during NPAA consumption (see below).
Moreover, for ease of
presentation, values were summed for Ile, Val and Leu (branched-chain amino acids
(BCAAs)). Statistical analysis (one way ANOVA with Tukey post-hoc) compared cohorts
with and without NPAAs, and within genotype only (*p<0.05 compared to control).
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Figure 4.1.b. Brain LNAA and SAMe as a function of diet (MAIB) and genotype (T,
Pah+/; M, Pah-/-). Evaluation of dietary intervention with 3% MAIB in Pahenu2 mice.
Statistical analysis (unpaired two-tail t-test) compared cohorts with and without MAIB,
and within genotype only (*p<0.05 compared to control).

4.3.

Amino acids in sera

Quantification of amino acids in sera provides an indication of possible LAT
competition and nutrient absorption in the gut. Analyses of amino acids in sera
demonstrated fewer significant differences and more variability than those in
brain (Fig. 4.2) (potentially associated with smaller subject numbers for NL).
Further, small sera volumes did not enable us to measure SAMe and SAH. AIB
intervention had a significant impact on blood Met (consistent with brain results)
and Trp (Fig. 4.2.a). None of the dietary interventions significantly altered blood
Phe, perhaps suggesting a lack of effect on Phe uptake in the gut. We again
performed t-test analyses for each intervention as a function of genotype, and
observed significant differences between Pah+/- and Pah-/- subjects as follows:
Phe (control and all diets, as expected); Tyr, both control and NB feeding;
BCAAs, control only. There were no significant differences observed for Trp and
Met. The trend for sera BCAA was toward higher levels in Pah-/- subjects, which
could potentially reflect catabolism associated with muscle proteolysis and BCAA
release.
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Pah+/; M, Pah-/-). See Fig. 4.1.a legend for abbreviations and statistical analysis. Note:
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brain SAH shown in the bottom right quadrant (pertinent to Fig. 4.1.b). No significant
alteration of serum LNAAs occurred with MAIB feeding.

4.4.

Catecholamine levels in brain

Determining deficiency or restoration of serotonin, 5-HT and/or dopamine, DA,
precursors and turnover in the brain signifies important effects of NPAA
administration on locomotor and social function in the mice. Catecholamine
analyses with respect to dietary intervention are shown in Fig. 4.3.a,b. There
were no differences for DOPAC, HVA and DA release (quantified as the 3MT/DA ratio with respect to AIB, NL, or NB for either genotype. For MAIB, these,
as well as 3-MT, were decreased in the brain for both genotypes. MAIB feeding
reduced metabolites in the DA and 5-HT systems. In the Pah-/-mouse, the
turnover of DA and 5-HT were reduced, and in the Pah+/- mouse DA and 5-HT
themselves were reduced. AIB feeding did not alter any metabolite with respect
to control cohorts (Fig. 4.3.a). NL feeding did not significantly alter the DA
system, but did impact 5-HT and 5-HIAA levels in Pah+/- subjects. NB feeding
markedly affected both DA and 5-HT systems (Fig. 4.3.a), with significant
decreases of DA in both genotypes, and 3-MT in Pah-/- subjects. As well, NB
significantly decreased 5-HT in Pah+/- and Pah-/- subjects. NB feeding did not
alter 5-HIAA levels in either genotype, while the turnover of both DA and 5-HT
was markedly increased in both Pah+/- and Pah-/- subjects. Again, t-test analyses
for each dietary intervention as a function of genotype were carried out, which
revealed significant differences between Pah+/- and Pah-/- subjects as follows:
DA, control and all diets except NL (this was also the case for 5-HT turnover); 3MT, all diets but not the control cohort; 5-HT and 5-HIAA, all groups and
interventions; and DA turnover, only for NL and NB. Overall, these findings
agree with previous analyses of PKU mice, with the exception of a lack of
significant difference in the control cohort for DA turnover.
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Figure 4.3.a. Brain catecholamines as a function of diet (NL, NB, AIB) and genotype
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Figure 4.3.b. Brain catecholamines as a function of diet (MAIB) and genotype (T,
Pah+/; M, Pah-/-). Statistical analysis performed as for Figs. 4.1.b & 4.2.b (* p<0.05).

4.5.

NPAA levels in brain and blood

NPAA consumption does not guarantee absorption or transport. Ideally,
systemic and repetitive measurement would provide the best measure of the
pharmacokinetics and dose-response to validate the Phe-reducing capacity of
our interventions. To this end, both NL and NB have been quantified in terminal
samples of sera and brain using an HPLC-based methodology. In five subjects,
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the sera NL concentration was 3.11 + 0.41 mM (SD; range 2.57-4.75) while that
in brain was 822 + 27 nmol/g tissue (assuming a tissue density approximating
water, ~0.82 µM). For NB, the sera concentration was 0.21 + 0.11 mM (SD;
range 0.08-0.31, n=4), while that in brain was 276 + 104 nmol/g tissue (n=9), or
~0.28 µM. These values indicate both absorption and uptake into brain, and
roughly reflect the 10-fold difference in level of application (5% NL, 0.5% NB).
An HPLC and tandem mass spectrometry-based method to quantify both AIB
and MAIB in tissue extracts and blood is in progress.

4.6.

Effect of NL feeding on blood chemistries

Subjects (Pah+/-) were supplemented with 5% NL (n=7) or standard chow (n=6)
for 3 weeks, after which sera was isolated for blood chemistries. The latter
included glucose, blood urea nitrogen (BUN), creatinine, total protein, albumin,
phosphorus, Na+, Cl-, K+, total CO2, cholesterol, triglycerides, Ca++, total bilirubin,
alkaline phosphatase (ALP), alanine aminotransferase, and gammaglutamyltransferase. No significant differences were observed between cohorts,
with two exceptions: BUN (5.43 + 0.30 mg/dL (+NL) vs. 3.83 + 0.17 (no NL)
(p=0.001; two-tailed t-test); and ALP (41.6 + 4.0 U/L (+ NL) vs. 57.7 + 2.3 (no NL)
(p=0.0065). It is unclear why NL supplementation would depress ALP, since
other hepatic enzymes were normal. On the other hand, it appears that NL is
contributing to an increased BUN via transamination, and thus careful monitoring
of blood chemistries will be prudent for future studies. This observation suggests
that NL is at least somewhat metabolizable in the body, perhaps in the liver, but
also potentially by intestinal bacteria (Der Garabedian and Vermeersch 1987).

5.

Discussion

These interventional studies represent the first application of NL and AIB in an
model of PKU, and the first in vivo application of NB in any mammal. MAIB has
been used to study transport of amino acids across the blood-nerve barrier in
rats, where MAIB was found to have no inhibitory effect on blood to nerve influx
of Phe using intravenous injection (Wadhwani et al. 1990). The Phe-reducing
capacity of both NL, NB (Fig. 4.1.a) and MAIB (Fig. 4.1.b) provides proof-ofprinciple to support further characterization of these compounds. Unfortunately,
neither species selectively acted on Phe (at the concentrations employed), with
significant effects on other LNAAs and catecholamines. NL did, however,
normalize DA levels and 5-HT turnover between genotypes, pointing to a positive
effect on catecholamines. Despite its inability to lower Phe, AIB warrants further
evaluation at higher concentrations, especially since its effects on other
biomarkers (LNAAs, catecholamines, etc.) were much milder than those of NL
and NB.
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A novel finding in these studies was the effect of MAIB on LNAA transport. MAIB
is purported to be a specific A-system inhibitor (Fig. 1.5), yet it significantly
reduced Phe and other LNAAs, and had a pronounced effect on the dopamine
system in both genotypes. Overall the data suggests that MAIB may be the
target compound with the most potential to reduce Phe with the least effect on
other LNAAs in the brain. Indeed, feeding of 3% MAIB had no effect on Met and
Trp, and the mildest effect on Tyr of any of the treatments attempted (-1:30 ,
56:55 , 27:86, 14:25, percent decrease Phe:Tyr for 5% AIB, 5% NL, 0.5% NB,
and 3% MAIB respectively as compared with control diet (Table 5.1). Data is
currently being collected to confirm that MAIB altered small amino acid levels in
the brain, such as alanine and proline.
Table 5.1.
NPAA effects on Phe and Tyr in Pah-/- subjects. *mean value in nmol/g

Phenylalanine
Diet
means*
p-value
percent ↓

(-)
(-)
18%
5% AIB 5% NL
0.5% NB 18%X
3% MAIB
759
764
333
552
782
671
p=0.96
p=0.002 p=0.026
p=0.002
-1
56
27
14

Diet
means*
p-value
percent ↓

Tyrosine
(-)
(-)
18%
5% AIB 5% NL
0.5% NB 18%X
3% MAIB
207
144
93
29
28
21
p=0.056 p=0.01
p=0.0002
p=0.049
30
55
86
25

As revealed in these studies, a major challenge will be to minimize LNAA effects
(other than Phe) with our interventions. Monoamine and LNAA data indicate that
5% and 0.5% NL and NB, respectively, are too high and 5% AIB is insufficient for
optimal intervention. Tyr levels were clearly impacted, and to a lesser extent Met
and BCAA levels (Fig. 4.1.a). Moreover, despite an absence of altered Trp
levels, we observed significant alterations of the serotonin system along with
dopamine disturbances (Fig. 4.3.a). Mounting evidence indicates that
dopaminergic and serotoninergic disruptions in PKU patients contribute
significantly to long-term pathophysiology (Waisbren et al. 2010; de Groot et al.
2010; Brumm et al. 2010; Banerjee et al. 2011). Biosafety information for our
NPAAs will have utility in terms of preclinical studies. Anecdotal evidence
suggests that NL, AIB, NB and MAIB are not extensively metabolized in
mammals, yet systematic metabolic analyses for any of these compounds is
lacking, and will also be investigated in further studies. As well, NPAAs not
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degraded by mammalian cells may still be metabolized by intestinal bacteria. For
example, NL is transaminated in the gut by Candida, and it may be a substrate
for amino acid oxidase (Der Garabedian and Vermeersch 1987). Indeed,
serological data indicates that feeding 5% NL to Pah+/- subjects elevated blood
urea nitrogen. AIB (also called 2-methylalanine) is metabolized by at least one
bacteria (Aaslestad et al. 1964). No data is available on the metabolism of MAIB
or NB in mammals.
The approach employing NPAAs should be applicable to another disorder of
LNAA metabolism, MSUD (maple syrup urine disease), a screenable disorder in
which the primary amino acids that accumulate to supraphysiological levels are
leucine, isoleucine and valine. Knudsen and colleagues (1995) documented
competition between Phe and Leu for uptake across the BBB in PKU patients,
and the Km values for Phe (32 + 9 µM) and Leu (87 + 11 µM) uptake into rat brain
are comparable (Pardridge et al. 1975), all of which leads to the conclusion that
NPAA intervention should be efficacious in MSUD (Zinnanti et al. 2009).
Similarities in pathomechanisms do not imply comparable pathophysiology,
however, and preclinical studies comparable to those outlined above would be
required in the corresponding MSUD animal model (Skvorak et al 2009a; 2009b;
Strauss et al. 2010).
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6.

Future directions

In these studies, the variable of nitrogen load in the control cohort was not fully
addressed; however, in future studies, casein in control (no NPAA) cohorts will
be used to attempt to control for nitrogen load with NPAA administration. Casein,
a milk protein utilized by Harlan-Teklad in the preparation of their rodent diets
(www.harlan.com), will be used to attempt to maintain isocaloric and nitrogenbalanced diets for control cohorts. Additionally, optimal NPAA interventions will
be examined in combination with regular (Teklad T.2018M; 18% protein) and low
protein (Teklad TD.90016; 6% protein) diets that will recapitulate the clinical
setting of PKU patients. Similarly, examination of NPAAs in Phe-limited chow
would most closely mimic the clinical situation for long-term studies.
The long-range goal of these studies is to find a combination of NPAA
interventions that can selectively block gut absorption and brain transport of Phe
with minimal impact on other LNAAs. While optimistic about this goal, an
additional approach is to consider supplementation of downstream LNAA
analogues in my studies in the Pahenu2 mouse. Three compounds, SAMe,
nitisinone, and 5-HTP (Table 6.1; Fig. 6.1), are proposed to potentially
circumvent the problems associated with non-Phe inhibition of LAT. Optimally,
the intermediates should employ non-LAT systems for brain access, since the
latter is our therapeutic target. This is the case for SAMe and nitisinone, but
remains in question for 5-HTP. Some evidence suggests that 5-HTP (the
serotonin precursor) accesses the brain via the serotonin (5-HT) transporter, but
there is no consensus and it may be partially moved on the LAT (Nakatani et al.
2008). The rationale for the application of nitisinone in these studies centers on
blocking systemic Tyr degradation (the clinical efficacy of this drug applicable to
tyrosinemia type I) with concomitant elevation of circulating Tyr (McKiernan
2006). The latter should lead to increased brain Tyr, but there may be
competition with the NPAAs. Nonetheless, additional competition from 5-HTP
and Tyr (associated with nitisinone administration) with different LATs would be
desirable and may further curtail brain Phe levels. Since it utilizes the nucleoside
transporter, SAMe intervention avoids concerns with LAT competition (Chishty et
al. 2002), and is rational based upon preliminary findings with NL (Fig. 4.1.a).
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Table 6.1.
NPAA interventions proposed to counteract NPAA-related decreases of non-Phe
LNAAs. *(NTBC,2 -[2-nitro-4-(trifluoromethyl)benzoyl] cyclohexane-1,3-dione), an
inhibitor of Tyr degradation.

Compound

Transporter

Rationale

Citations

5-HTP

5-HT

Bypass LAT, maintain 5-HT
level

(Andolina et al.
2011)

NTBC*
Nitisinone

-

Increase systemic Tyr,
raise DA level

(McKiernan 2006)

SAMe

Nucleoside

Bypass LAT, offset Met
depletion

(Chishty et al.
2002)

Figure 6.1. Supplements proposed to bypass LAT.
Chemical structures of
interventions employed to supplement non-Phe LNAA decreases during NPAA
intervention.

An additional strategy is supplementation of threonine (Thr). Segawa and
colleagues (1999) provided evidence for a Na+-independent intestinal transport
system for Phe and Thr, and Sanjurjo and coworkers (2003) built upon this
observation by demonstrating a significant reduction of blood Phe in PKU
patients receiving Thr supplementation, presumably the result of decreased
intestinal absorption of Phe due to competition (Sanjurjo et al. 2003). Thr
supplementation has not been piloted in Pah-/- mice, and its use in combination
with our NPAAs may provide a more even mix of essential amino acids in the
murine system, but the risk with Thr feeding is that the patient, or mouse, is
driven into negative nitrogen balance. Conversely, glycomacropeptide (GMP;
substantially Phe-free) has been successfully piloted in Pah-/- mice (Ney et al.
2008; Laclair et al. 2009). GMP administration significantly increases blood Thr,
while simultaneously generating an inverse correlation between Thr and Phe in
brain (decreased Phe with increasing Thr). Accordingly, GMP may represent
another mechanism for increasing Thr in Pah-/- mice and further inhibiting Phe
transport into brain. In the long run, however, the goal is to utilize only one (or
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more) of the NPAAs piloted in this thesis work to selectively lower Phe content in
brain. The use of additional interventions (SAMe, nitisinone and 5-HTP) would
be a complicated approach in a patient, might not be significantly more welcome
by patients than the protein-restricted diet, and actually might have more
potentially negative downstream metabolic effects than just the NPAAs alone.
Catecholamines in these studies employed ½-brains (sagitally sectioned), which
may not be optimal. For example, it is possible that the DA level determined in
½-brain extract was misleading (Fig. 4.3.a), such that low levels of DA in striatum
may have been “normalized” via mixing of higher DA levels in cortex or
cerebellum (or other brain regions) (Bortolozzi et al. 2003). With this rationale in
mind, dissected brain regions, including cortex, striatum, cerebellum and
hippocampi will be monitored during catecholamine measurements in future
work. Additionally, neurobehavioral assessments will be made to complement
terminal catecholamine quantifications once more optimal NPAA interventions
and combinations are assessed. The rationale for behavioral assessment
focuses primarily on the neurocognitive deficits observed in PKU patients
(Banerjee et al. 2011), as well as the roles of DA and 5-HT in cognition and
movement (Uddén et al. 2010). Locomotor, anxiety, and non-spatial memory are
relevant endpoints for Pah-/- subjects. For initial motor evaluation, subjects are
characterized using a quantitative neurological scale (0, normal animal; 10,
animal displaying near-death recumbency) that examines dystonic movement
and behavior (Ouary et al. 2000; Zinnanti et al 2009; Zinnanti et al. 2012).
Visual-cliff avoidance response (CAR) gauges teratological learning impairment
in mice (Yoshida et al. 2000). Additionally, open field (OF) activity will be used to
obtain a broader behavioral coverage of serotoninergic function (Singer et al.
2009). The OF test assesses exploratory and anxiety-like behavior, a useful
measure of behavioral response to novelty (see Fig. 6.2). The Gibson laboratory
OF area consists of an enclosed white circular arena, with division markings and
floor holes. Animals experiencing higher anxiety will remain in the outermost
circle of the arena, avoiding the center (thigmotaxis). In addition, the number of
head dips and the novel object test evaluates the animal’s exploration of the field.
Locomotor activity parameters measured include: quadrant transitions and
velocity, as well as the number of quadrants explored. These evaluations should
represent valid surrogates for behavior associated with DA and 5-HT function,
and can be assessed during intervention without the need to sacrifice the animal.
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Figure 6.2. Open field testing paradigm for behavioral testing in mice. Three zone
groups are established to determine anxiety, non-spatial memory, and locomotor activity.

Finally, since a primary goal of PKU intervention is to examine therapeutic
strategies that improve cognitive dysfunction, the memory of Pahenu2 mice
receiving NPAA administration must be explored. The object recognition (OR)
test evaluates non-spatial working memory and is based on the premise that
mice are instinctively curious. Outputs measures here include the amount of
time spent in the zone of the familiar versus novel object. First the activity in the
arena is recorded in the settings with two familiar objects. After a rest outside the
field, the animal is replaced into the same quadrant and left to explore the novel
object, with the assumption that animals with higher working memory will
investigate the novel object preferentially (Bevins et al. 2006). Noldus Ethovision
software and video recording will be used to track animals in the field, providing
the outputs described for the OF and novelty testing for the mice. An example of
the zoning and quadrature of the field is depicted in Fig. 6.2. Overall, these
behavioral tests will gauge anxiety, memory, exploratory and locomotor activity
providing important behavioral readouts for the effectiveness of interventions
used to treat Pahenu2 mice.
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7.

Conclusion

NL, NB and MAIB have significantly reduced Phe levels in the phenylketonuric
mouse brain, but with concomitant alterations of important biomolecules for
serotoninergic and dopaminergic neurotransmission, and other LNAAs.
Nonetheless, the pilot data shown in this thesis indicates that this novel approach
is feasible and may be the genesis of a totally new treatment for PKU patients.
Moreover, for the first time here it is shown that a system A specific inhibitor,
MAIB, may have important utility as a LAT-1 inhibitor, and this has not been
reported in the literature. Utilizing NPAAs to reduce cerebral Phe transport is
pertinent to the long-term objective of employing oral NPAA intervention(s) in
patients for whom dietary adherence to low-protein intake is suboptimal, and
potentially to identify NPAA interventions that would enable normal dietary
protein intake for patients. What remains as a barrier is to optimize
concentration, possibly in combinatorial dosages of NPAA, to produce a cocktail
with selective Phe-inhibiting capacity.

30

8.

Bibliography

Aaslestad, H G, and A D LARSON. 1964. “Bacterial Metabolism of 2Methylalanine.” Journal of Bacteriology 88 (November): 1296–1303.
Anastasoaie, Vera, Laura Kurzius, Peter Forbes, and Susan Waisbren. 2008.
“Stability of Blood Phenylalanine Levels and IQ in Children with
Phenylketonuria.” Molecular Genetics and Metabolism 95 (1-2) (October):
17–20. doi:10.1016/j.ymgme.2008.06.014.
Anderson, Peter J, and Vincenzo Leuzzi. 2010. “White Matter Pathology in
Phenylketonuria.” Molecular Genetics and Metabolism 99 Suppl 1: S3–9.
doi:10.1016/j.ymgme.2009.10.005.
Anderson, Peter J, Stephen J Wood, Dorothy E Francis, Lee Coleman, Vicki
Anderson, and Avihu Boneh. 2007. “Are Neuropsychological Impairments
in Children with Early-treated Phenylketonuria (PKU) Related to White
Matter Abnormalities or Elevated Phenylalanine Levels?” Developmental
Neuropsychology 32 (2): 645–668. doi:10.1080/87565640701375963.
Andolina, Diego, David Conversi, Simona Cabib, Antonio Trabalza, Rossella
Ventura, Stefano Puglisi-Allegra, and Tiziana Pascucci. 2011. “5Hydroxytryptophan During Critical Postnatal Period Improves Cognitive
Performances and Promotes Dendritic Spine Maturation in Genetic Mouse
Model of Phenylketonuria.” The International Journal of
Neuropsychopharmacology 14 (4) (May): 479–489.
doi:10.1017/S1461145710001288.
Antoshechkin, A G, T V Chentsova, Tatur VYu, D B Naritsin, and G P Railian.
1991. “Content of Phenylalanine, Tyrosine and Their Metabolites in CSF in
Phenylketonuria.” Journal of Inherited Metabolic Disease 14 (5): 749–754.
Babu, Ellappan, Yoshikatsu Kanai, Arthit Chairoungdua, Do Kyung Kim, Yuji
Iribe, Sahatchai Tangtrongsup, Promsuk Jutabha, et al. 2003.
“Identification of a Novel System L Amino Acid Transporter Structurally
Distinct from Heterodimeric Amino Acid Transporters.” J. Biol. Chem. 278
(44) (October 31): 43838–43845. doi:10.1074/jbc.M305221200.
Banerjee, Pia, Dorothy K Grange, Robert D Steiner, and Desirée A White. 2011.
“Executive Strategic Processing During Verbal Fluency Performance in
Children with Phenylketonuria.” Child Neuropsychology: A Journal on
Normal and Abnormal Development in Childhood and Adolescence 17 (2):
105–117. doi:10.1080/09297049.2010.525502.
Barretto, Junaura Rocha, Luciana Rodrigues Silva, Maria Efigênia Leite, Ney
Boa-Sorte, Helena Pimentel, Antonio Conceição Purificação, Gildasio
Carvalho, Maria Inês M M Fontes, and Tatiana Amorim. 2008. “Poor Zinc
and Selenium Status in Phenylketonuric Children and Adolescents in
31

Brazil.” Nutrition Research (New York, N.Y.) 28 (3) (March): 208–211.
doi:10.1016/j.nutres.2007.12.009.
Bevins, Rick A, and Joyce Besheer. 2006. “Object Recognition in Rats and Mice:
a One-trial Non-matching-to-sample Learning Task to Study ‘Recognition
Memory’.” Nature Protocols 1 (3) (October 12): 1306–1311.
doi:10.1038/nprot.2006.205.
Bodoy, Susanna, Lorena Martín, Antonio Zorzano, Manuel Palacín, Raúl
Estévez, and Joan Bertran. 2005. “Identification of LAT4, a Novel Amino
Acid Transporter with System L Activity.” Journal of Biological Chemistry
280 (12) (March 25): 12002 –12011. doi:10.1074/jbc.M408638200.
Bortolozzi, Analía, Ricardo Duffard, and Ana María Evangelista de Duffard. 2003.
“Asymmetrical Development of the Monoamine Systems in 2,4dichlorophenoxyacetic Acid Treated Rats.” Neurotoxicology 24 (1)
(January): 149–157.
Brown, R E, D R Stevens, and H L Haas. 2001. “The Physiology of Brain
Histamine.” Progress in Neurobiology 63 (6) (April): 637–672.
Brumm, V L, D Bilder, and S E Waisbren. 2010. “Psychiatric Symptoms and
Disorders in Phenylketonuria.” Molecular Genetics and Metabolism 99
Suppl 1: S59–63. doi:10.1016/j.ymgme.2009.10.182.
Chishty, M., A. Reichel, N.J. Abbott, and D.J. Begley. 2002. “Sadenosylmethionine Is Substrate for Carrier Mediated Transport at the
Blood–brain Barrier in Vitro.” Brain Research 942 (1-2) (June): 46–50.
doi:10.1016/S0006-8993(02)02654-9.
Christensen, H N, and J T Rothwell. 1948. “Association Between Rapid Growth
and Elevated Cell Concentrations of Amino Acids; in Regenerating Liver
After Partial Hepatectomy in the Rat.” The Journal of Biological Chemistry
175 (1) (August): 101–105.
Colomé, Catrina, Rafael Artuch, Maria-Antònia Vilaseca, Cristina Sierra, Núria
Brandi, Nilo Lambruschini, Francisco J Cambra, and Jaume Campistol.
2003. “Lipophilic Antioxidants in Patients with Phenylketonuria.” The
American Journal of Clinical Nutrition 77 (1) (January 1): 185–188.
de Groot, M J, M Hoeksma, N Blau, D J Reijngoud, and F J van Spronsen. 2010.
“Pathogenesis of Cognitive Dysfunction in Phenylketonuria: Review of
Hypotheses.” Molecular Genetics and Metabolism 99 Suppl 1: S86–89.
doi:10.1016/j.ymgme.2009.10.016.
Der Garabedian, P A, and J J Vermeersch. 1987. “Candida Lnorleucine,leucine:2-oxoglutarate Aminotransferase. Purification and
Properties.” European Journal of Biochemistry / FEBS 167 (1) (August
17): 141–147.
32

Dokoupil, Katharina, Hulya Gokmen-Ozel, Anna Maria Lammardo, Kristina
Motzfeldt, Martine Robert, Júlio César Rocha, Margreet van Rijn, Kirsten
Ahring, Amaya Bélanger-Quintana, and Anita Macdonald. 2011.
“Optimising Growth in Phenylketonuria: Current State of the Clinical
Evidence Base.” Clinical Nutrition (Edinburgh, Scotland) (September 27).
doi:10.1016/j.clnu.2011.09.001.
http://www.ncbi.nlm.nih.gov/pubmed/21959353.
Dotremont, H, B François, M Diels, and P Gillis. 1995a. “Nutritional Value of
Essential Amino Acids in the Treatment of Adults with Phenylketonuria.”
Journal of Inherited Metabolic Disease 18 (2): 127–130.
Dyer, Charissa A. 1999. “Pathophysiology of Phenylketonuria.” Mental
Retardation and Developmental Disabilities Research Reviews 5 (2): 104–
112. doi:10.1002/(SICI)1098-2779(1999)5:2<104::AID-MRDD2>3.0.CO;27.
Enns, G M, R Koch, V Brumm, E Blakely, R Suter, and E Jurecki. 2010.
“Suboptimal Outcomes in Patients with PKU Treated Early with Diet
Alone: Revisiting the Evidence.” Molecular Genetics and Metabolism 101
(2-3) (November): 99–109. doi:10.1016/j.ymgme.2010.05.017.
Erlandsen, H, and R C Stevens. 1999. “The Structural Basis of Phenylketonuria.”
Molecular Genetics and Metabolism 68 (2) (October): 103–125.
doi:10.1006/mgme.1999.2922.
Følling, I. 1994. “The Discovery of Phenylketonuria.” Acta Paediatrica (Oslo,
Norway: 1992). Supplement 407 (December): 4–10.
Harding, Cary O. 2010. “New Era in Treatment for Phenylketonuria:
Pharmacologic Therapy with Sapropterin Dihydrochloride.” Biologics:
Targets & Therapy 4: 231–236.
Hörster, Friederike, Marina A Schwab, Sven W Sauer, Joachim Pietz, Georg F
Hoffmann, Jürgen G Okun, Stefan Kölker, and Stefan Kins. 2006.
“Phenylalanine Reduces Synaptic Density in Mixed Cortical Cultures from
Mice.” Pediatric Research 59 (4 Pt 1) (April): 544–548.
doi:10.1203/01.pdr.0000203091.45988.8d.
Huttenlocher, P R. 2000. “The Neuropathology of Phenylketonuria: Human and
Animal Studies.” European Journal of Pediatrics 159 Suppl 2 (October):
S102–106.
Hvas, A M, E Nexo, and J B Nielsen. 2006. “Vitamin B12 and Vitamin B6
Supplementation Is Needed Among Adults with Phenylketonuria (PKU).”
Journal of Inherited Metabolic Disease 29 (1) (February): 47–53.
doi:10.1007/s10545-006-0108-3.

33

Joseph, Bernadin, and Charissa A Dyer. 2003. “Relationship Between Myelin
Production and Dopamine Synthesis in the PKU Mouse Brain.” Journal of
Neurochemistry 86 (3) (August): 615–626.
Kanai, Yoshikatsu, Hiroko Segawa, Ken-ichi Miyamoto, Hiroshi Uchino, Eiji
Takeda, and Hitoshi Endou. 1998. “Expression Cloning and
Characterization of a Transporter for Large Neutral Amino Acids Activated
by the Heavy Chain of 4F2 Antigen (CD98).” Journal of Biological
Chemistry 273 (37): 23629 –23632. doi:10.1074/jbc.273.37.23629.
Kaufman, S. 1986. “Regulation of the Activity of Hepatic Phenylalanine
Hydroxylase.” Advances in Enzyme Regulation 25: 37–64.
Knudsen, G M, S Hasselbalch, P B Toft, E Christensen, O B Paulson, and H Lou.
1995. “Blood-brain Barrier Transport of Amino Acids in Healthy Controls
and in Patients with Phenylketonuria.” Journal of Inherited Metabolic
Disease 18 (6): 653–664.
Koura, Hala M., Nagwa Abdallah Ismail, Ashraf F. Kamel, Azza M Ahmed, Amal
Saad-Hussein, and Laila K. Effat. 2011. “A Long-term Study of Bone
Mineral Density in Patients with Phenylketonuria Under Diet Therapy.”
Archives of Medical Science : AMS 7 (3) (June): 493–500.
doi:10.5114/aoms.2011.23417.
Laclair, Caitlin E, Denise M Ney, Erin L MacLeod, and Mark R Etzel. 2009.
“Purification and Use of Glycomacropeptide for Nutritional Management of
Phenylketonuria.” Journal of Food Science 74 (4) (July): E199–206.
doi:10.1111/j.1750-3841.2009.01134.x.
Lee, Bor Jen, Ping Ting Lin, Yung Po Liaw, Sue Joan Chang, Chien Hsiung
Cheng, and Yi Chia Huang. 2003. “Homocysteine and Risk of Coronary
Artery Disease: Folate Is the Important Determinant of Plasma
Homocysteine Concentration.” Nutrition (Burbank, Los Angeles County,
Calif.) 19 (7-8) (August): 577–583.
Lidsky, A S, M L Law, H G Morse, F T Kao, M Rabin, F H Ruddle, and S L Woo.
1985. “Regional Mapping of the Phenylalanine Hydroxylase Gene and the
Phenylketonuria Locus in the Human Genome.” Proceedings of the
National Academy of Sciences of the United States of America 82 (18)
(September): 6221–6225.
Lutz, P, H Schmidt, and U Batzler. 1990. “Study Design and Description of
Patients.” European Journal of Pediatrics 149 Suppl 1: S5–12.
Lutz, P, H Schmidt, G Frey, and H Bickel. 1982. “Standardized Loading Test with
Protein for the Differentiation of Phenylketonuria from
Hyperphenylalaninaemia.” Journal of Inherited Metabolic Disease 5 (1):
29–35.

34

Matalon, R, K Michals-Matalon, G Bhatia, E Grechanina, P Novikov, J D
McDonald, J Grady, S K Tyring, and F Guttler. 2006. “Large Neutral
Amino Acids in the Treatment of Phenylketonuria (PKU).” Journal of
Inherited Metabolic Disease 29 (6) (December): 732–738.
doi:10.1007/s10545-006-0395-8.
McDonald, J D, V C Bode, W F Dove, and A Shedlovsky. 1990. “Pahhph-5: a
Mouse Mutant Deficient in Phenylalanine Hydroxylase.” Proceedings of
the National Academy of Sciences of the United States of America 87 (5)
(March): 1965–1967.
McKean, C M, D E Boggs, and N A Peterson. 1968. “The Influence of High
Phenylalanine and Tyrosine on the Concentrations of Essential Amino
Acids in Brain.” Journal of Neurochemistry 15 (3) (March): 235–241.
McKiernan, Patrick J. 2006. “Nitisinone in the Treatment of Hereditary
Tyrosinaemia Type 1”. Text. zotero://attachment/388/.
Michals-Matalon, Kimberlee, Gita Bhatia, Flemming Guttler, Stephen K Tyring,
and Reuben Matalon. 2007. “Response of Phenylketonuria to
Tetrahydrobiopterin.” The Journal of Nutrition 137 (6 Suppl 1) (June):
1564S–1567S; discussion 1573S–1575S.
Muntau, Ania C, Wulf Röschinger, Matthias Habich, Hans Demmelmair, Björn
Hoffmann, Christian P Sommerhoff, and Adelbert A Roscher. 2002.
“Tetrahydrobiopterin as an Alternative Treatment for Mild
Phenylketonuria.” The New England Journal of Medicine 347 (26)
(December 26): 2122–2132. doi:10.1056/NEJMoa021654.
Nakatani, Yasushi, Ikuko Sato-Suzuki, Naohisa Tsujino, Akane Nakasato,
Yoshinari Seki, Masaki Fumoto, and Hideho Arita. 2008. “Augmented
Brain 5-HT Crosses the Blood-brain Barrier Through the 5-HT Transporter
in Rat.” The European Journal of Neuroscience 27 (9) (May): 2466–2472.
doi:10.1111/j.1460-9568.2008.06201.x.
Ney, Denise M, Angela K Hull, Sandra C van Calcar, Xiaowen Liu, and Mark R
Etzel. 2008. “Dietary Glycomacropeptide Supports Growth and Reduces
the Concentrations of Phenylalanine in Plasma and Brain in a Murine
Model of Phenylketonuria.” The Journal of Nutrition 138 (2) (February):
316–322.
NIH 2001. “National Institutes of Health Consensus Development Conference
Statement: Phenylketonuria: Screening and Management, October 16-18,
2000.” Pediatrics 108 (4) (October): 972–982.
Nishihira, T, T Takagi, and S Mori. 1993. “Amino Acid Imbalance and Intracellular
Protein Synthesis.” Nutrition (Burbank, Los Angeles County, Calif.) 9 (1)
(February): 37–42.

35

Ogawa, Shintaro, and Hiroshi Ichinose. 2006. “Effect of Metals and
Phenylalanine on the Activity of Human Tryptophan Hydroxylase-2:
Comparison with That on Tyrosine Hydroxylase Activity.” Neuroscience
Letters 401 (3) (July 3): 261–265. doi:10.1016/j.neulet.2006.03.031.
Ogburn, Kenyon D, Teodoro Bottiglieri, Zhiyou Wang, and Maria E FigueiredoPereira. 2006. “Prostaglandin J2 Reduces catechol-O-methyltransferase
Activity and Enhances Dopamine Toxicity in Neuronal Cells.”
Neurobiology of Disease 22 (2) (May): 294–301.
doi:10.1016/j.nbd.2005.11.006.
Ouary, S, N Bizat, S Altairac, H Ménétrat, V Mittoux, F Condé, P Hantraye, and E
Brouillet. 2000. “Major Strain Differences in Response to Chronic
Systemic Administration of the Mitochondrial Toxin 3-nitropropionic Acid in
Rats: Implications for Neuroprotection Studies.” Neuroscience 97 (3):
521–530.
Pardridge, W M, and W H Oldendorf. 1975. “Kinetic Analysis of Blood-brain
Barrier Transport of Amino Acids.” Biochimica Et Biophysica Acta 401 (1)
(August 5): 128–136.
Pascucci, Tiziana, Rossella Ventura, Stefano Puglisi-Allegra, and Simona Cabib.
2002. “Deficits in Brain Serotonin Synthesis in a Genetic Mouse Model of
Phenylketonuria.” Neuroreport 13 (18) (December 20): 2561–2564.
doi:10.1097/01.wnr.0000047690.08940.39.
Pavon, Jorge Alex, and Paul F Fitzpatrick. 2006. “Insights into the Catalytic
Mechanisms of Phenylalanine and Tryptophan Hydroxylase from Kinetic
Isotope Effects on Aromatic Hydroxylation.” Biochemistry 45 (36)
(September 12): 11030–11037. doi:10.1021/bi0607554.
Pietz, J, R Kreis, A Rupp, E Mayatepek, D Rating, C Boesch, and H J Bremer.
1999. “Large Neutral Amino Acids Block Phenylalanine Transport into
Brain Tissue in Patients with Phenylketonuria.” The Journal of Clinical
Investigation 103 (8) (April): 1169–1178. doi:10.1172/JCI5017.
Pietz, Joachim, André Rupp, Friedrich Ebinger, Dietz Rating, Ertan Mayatepek,
Chris Boesch, and Roland Kreis. 2003. “Cerebral Energy Metabolism in
Phenylketonuria: Findings by Quantitative In Vivo 31P MR Spectroscopy.”
Pediatric Research 53 (4) (April): 654–662.
doi:10.1203/01.PDR.0000055867.83310.9E.
Puglisis-Allegra, Stefano, Simona Cabib, Tiziana Pascucci, Rossella Ventura,
Francesco Cali, and Valentino Romano. 2000. “Dramatic Brain Aminergic
Deficit in a Genetic Mouse Model of... : NeuroReport.” Neurochemistry 11
(6): 1361–1364.
Reilly, C, J E Barrett, C M Patterson, U Tinggi, S L Latham, and A Marrinan.
1990. “Trace Element Nutrition Status and Dietary Intake of Children with
36

Phenylketonuria.” The American Journal of Clinical Nutrition 52 (1) (July):
159–165.
Richardson, S C, R A Aspbury, and M J Fisher. 1993. “The Role of Reversible
Phosphorylation in the Hormonal Control of Phenylalanine Hydroxylase in
Isolated Rat Proximal Kidney Tubules.” Biochemical Journal 292 (Pt 2)
(June 1): 419–424.
Rossier, Grégoire, Christian Meier, Christian Bauch, Vanessa Summa, Bernard
Sordat, François Verrey, and Lukas C. Kühn. 1999. “LAT2, a New
Basolateral 4F2hc/CD98-associated Amino Acid Transporter of Kidney
and Intestine.” Journal of Biological Chemistry 274 (49) (December 3):
34948 –34954. doi:10.1074/jbc.274.49.34948.
Schindeler, Suzanne, Suparna Ghosh-Jerath, Susan Thompson, Antonella
Rocca, Pamela Joy, Allan Kemp, Caroline Rae, Kathryn Green, Bridget
Wilcken, and John Christodoulou. 2007. “The Effects of Large Neutral
Amino Acid Supplements in PKU: An MRS and Neuropsychological
Study.” Molecular Genetics and Metabolism 91 (1) (May): 48–54.
doi:10.1016/j.ymgme.2007.02.002.
Schulpis, K H, G A Karikas, and E Papakonstantinou. 2002. “Homocysteine and
Other Vascular Risk Factors in Patients with Phenylketonuria on a Diet.”
Acta Paediatrica (Oslo, Norway: 1992) 91 (8): 905–909.
Segawa, H, Y Fukasawa, K Miyamoto, E Takeda, H Endou, and Y Kanai. 1999.
“Identification and Functional Characterization of a Na+-independent
Neutral Amino Acid Transporter with Broad Substrate Selectivity.” The
Journal of Biological Chemistry 274 (28) (July 9): 19745–19751.
Shefer, S, G S Tint, D Jean-Guillaume, E Daikhin, A Kendler, L B Nguyen, M
Yudkoff, and C A Dyer. 2000a. “Is There a Relationship Between 3hydroxy-3-methylglutaryl Coenzyme a Reductase Activity and Forebrain
Pathology in the PKU Mouse?” Journal of Neuroscience Research 61 (5)
(September 1): 549–563.
Singer, Harvey S, Christina Morris, Colin Gause, Matthew Pollard, Andrew W
Zimmerman, and Mikhail Pletnikov. 2009. “Prenatal Exposure to
Antibodies from Mothers of Children with Autism Produces
Neurobehavioral Alterations: A Pregnant Dam Mouse Model.” Journal of
Neuroimmunology 211 (1-2) (June 25): 39–48.
doi:10.1016/j.jneuroim.2009.03.011.
Sitta, A, C S Vanzin, G B Biancini, V Manfredini, A B de Oliveira, C A Y Wayhs,
G O S Ribas, et al. 2011. “Evidence That L-carnitine and Selenium
Supplementation Reduces Oxidative Stress in Phenylketonuric Patients.”
Cellular and Molecular Neurobiology 31 (3) (April): 429–436.
doi:10.1007/s10571-010-9636-3.
37

Slocum, R.H., and J.G. Cummings. 1991. “Amino Acid Analysis of Physiological
Samples.” In Techniques in Diagnostic Human Biochemical Genetics, 87–
126. Wiley-Liss.
Smith, C B, and J Kang. 2000. “Cerebral Protein Synthesis in a Genetic Mouse
Model of Phenylketonuria.” Proceedings of the National Academy of
Sciences of the United States of America 97 (20) (September 26): 11014–
11019.
Strauss, Kevin A, Bridget Wardley, Donna Robinson, Christine Hendrickson,
Nicholas L Rider, Erik G Puffenberger, Diana Shellmer, Diana Shelmer,
Ann B Moser, and D Holmes Morton. 2010. “Classical Maple Syrup Urine
Disease and Brain Development: Principles of Management and Formula
Design.” Molecular Genetics and Metabolism 99 (4) (April): 333–345.
doi:10.1016/j.ymgme.2009.12.007.
Tews, J K, and A E Harper. 1986. “Tissue Amino Acids in Rats Fed Norleucine,
Norvaline, Homoarginine or Other Amino Acid Analogues.” The Journal of
Nutrition 116 (8) (August): 1464–1472.
Tews, J K, J J Repa, and A E Harper. 1990. “Norleucine: a Branched-chain
Amino Acid Analog Affecting Feeding Behavior of Rats.” Pharmacology,
Biochemistry, and Behavior 35 (4) (April): 911–921.
Tews, J K, J J Repa, and A E Harper. 1991. “Branched-chain and Other Amino
Acids in Tissues of Rats Fed Leucine-limiting Amino Acid Diets Containing
Norleucine.” The Journal of Nutrition 121 (3) (March): 364–378.
Tinggi, Ujang. 2008. “Selenium: Its Role as Antioxidant in Human Health.”
Environmental Health and Preventive Medicine 13 (2) (March 1): 102–108.
doi:10.1007/s12199-007-0019-4.
Uchino, Hiroshi, Yoshikatsu Kanai, Do Kyung Kim, Michael F. Wempe, Arthit
Chairoungdua, Emiko Morimoto, M. W. Anders, and Hitoshi Endou. 2002.
“Transport of Amino Acid-Related Compounds Mediated by L-Type Amino
Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate
Recognition.” Molecular Pharmacology 61 (4) (April 1): 729 –737.
doi:10.1124/mol.61.4.729.
Uddén, Julia, Vasiliki Folia, and Karl Magnus Petersson. 2010. “The
Neuropharmacology of Implicit Learning.” Current Neuropharmacology 8
(4) (December): 367–381. doi:10.2174/157015910793358178.
UK PubMed Central (UKPMC). 1995. “The Value of Posttransplant Monitoring of
Interleukin (IL)-2, IL-3, IL-4, IL-6, IL-8, and... - Abstract - UK PubMed
Central”. Journal Article. http://ukpmc.ac.uk/abstract/MED/7871561.
van Gool, Christel J.A.W, Adriana C van Houwelingen, and Gerard Hornstra.
2000. “The Essential Fatty Acid Status in Phenylketonuria Patients Under
38

Treatment.” The Journal of Nutritional Biochemistry 11 (11–12)
(November): 543–547. doi:10.1016/S0955-2863(00)00111-X.
van Spronsen, F J, Marieke Hoeksma, and Dirk-Jan Reijngoud. 2009. “Brain
Dysfunction in Phenylketonuria: Is Phenylalanine Toxicity the Only
Possible Cause?” Journal of Inherited Metabolic Disease 32 (1)
(February): 46–51. doi:10.1007/s10545-008-0946-2.
van Spronsen, Francjan J, Martijn J de Groot, Marieke Hoeksma, Dirk-Jan
Reijngoud, and Margreet van Rijn. 2010. “Large Neutral Amino Acids in
the Treatment of PKU: From Theory to Practice.” Journal of Inherited
Metabolic Disease 33 (6) (December): 671–676. doi:10.1007/s10545-0109216-1.
Verrey, François, Ellen I Closs, Carsten A Wagner, Manuel Palacin, Hitoshi
Endou, and Yoshikatsu Kanai. 2004. “CATs and HATs: The SLC7 Family
of Amino Acid Transporters.” Pflügers Archiv: European Journal of
Physiology 447 (5) (February): 532–542. doi:10.1007/s00424-003-1086-z.
Vogel, KR, FN Lambert, EA Arning, T Bottiglieri, and KM Gibson. 2012.
“Therapeutic Efficacy of Competitive Non-physiological Amino Acid
(NPAA) Intervention in Phenylketonuric Mice.” Molecular Genetics and
Metabolism 105 (3) (March): 114–115.
Wadhwani, K C, Q R Smith, and S I Rapoport. 1990. “Facilitated Transport of Lphenylalanine Across Blood-nerve Barrier of Rat Peripheral Nerve.” The
American Journal of Physiology 258 (6 Pt 2) (June): R1436–1444.
Waisbren, S, and D A White. 2010. “Screening for Cognitive and Socialemotional Problems in Individuals with PKU: Tools for Use in the
Metabolic Clinic.” Molecular Genetics and Metabolism 99 Suppl 1: S96–
99. doi:10.1016/j.ymgme.2009.10.006.
Williams, Robin A, Cyril DS Mamotte, and John R Burnett. 2008.
“Phenylketonuria: An Inborn Error of Phenylalanine Metabolism.” The
Clinical Biochemist Reviews 29 (1) (February): 31–41.
Yanagida, Osamu, Yoshikatsu Kanai, Arthit Chairoungdua, Do Kyung Kim,
Hiroko Segawa, Tomoko Nii, Seok Ho Cha, et al. 2001. “Human L-type
Amino Acid Transporter 1 (LAT1): Characterization of Function and
Expression in Tumor Cell Lines.” Biochimica Et Biophysica Acta (BBA) Biomembranes 1514 (2) (October 1): 291–302. doi:10.1016/S00052736(01)00384-4.
Yoshida, S, Y Numachi, H Matsuoka, and M Sato. 2000. “The Absence of
Impairment of Cliff Avoidance Reaction Induced by Subchronic
Methamphetamine Treatment in Inbred Strains of Mice.” The Tohoku
Journal of Experimental Medicine 190 (3) (March): 205–212.

39

Zagreda, L, J Goodman, D P Druin, D McDonald, and A Diamond. 1999.
“Cognitive Deficits in a Genetic Mouse Model of the Most Common
Biochemical Cause of Human Mental Retardation.” The Journal of
Neuroscience: The Official Journal of the Society for Neuroscience 19 (14)
(July 15): 6175–6182.
Zinnanti, William J, and Jelena Lazovic. 2012. “Interrupting the Mechanisms of
Brain Injury in a Model of Maple Syrup Urine Disease Encephalopathy.”
Journal of Inherited Metabolic Disease 35 (1) (January): 71–79.
doi:10.1007/s10545-011-9333-5.
Zinnanti, William J., Jelena Lazovic, Kathleen Griffin, Kristen J. Skvorak,
Harbhajan S. Paul, Gregg E. Homanics, Maria C. Bewley, Keith C. Cheng,
Kathryn F. LaNoue, and John M. Flanagan. 2009. “Dual Mechanism of
Brain Injury and Novel Treatment Strategy in Maple Syrup Urine Disease.”
Brain 132 (4) (April 1): 903 –918. doi:10.1093/brain/awp024.

40

